论文部分内容阅读
目的:评价双歧杆菌乳杆菌三联活菌片与标准“四联”疗法对胃幽门螺杆菌感染患者的临床疗效。方法:选取医院2014年12月—2016年12月期间收治的胃幽门螺杆菌感染患者84例临床资料,采用数字表法将其分为对照组与观察组(每组42例);对照组患者给予标准“四联”疗法(雷贝拉唑钠肠溶片、甲硝唑片、阿莫西林胶囊和胶体果胶铋胶囊)治疗,观察组患者在对照组治疗基础上加用双歧杆菌乳杆菌三联活菌片治疗,比较两组患者治疗后的总有效率、幽门螺杆菌的清除率与不良反应的发生率。结果:两组患者治疗后的总有效率、幽门螺杆菌的清除率经比较其差异无统计学意义(P>0.05);观察组患者用药期间不良反应的发生率为7.14%低于对照组为26.19%(P<0.05)。结论:双歧杆菌乳杆菌三联活菌片与标准“四联”疗法联用治疗胃幽门螺杆菌感染患者的临床疗效与标准“四联”疗法相似,但用药期间不良反应的发生率较低。
Objective: To evaluate the clinical efficacy of Lactobacillus bifidum triple active viable tablets and standard “quadruple” therapy on patients with Helicobacter pylori infection. Methods: The clinical data of 84 patients with Helicobacter pylori infection admitted from December 2014 to December 2016 in our hospital were selected and divided into control group and observation group (n = 42 in each group) Given standard “quadruple” therapy (rabeprazole sodium enteric-coated tablets, metronidazole tablets, amoxicillin capsules and colloidal pectin bismuth capsules) treatment, the observation group patients in the control group based on the use of bifid Bacillus coli Lactobacillus triple viable tablets treatment, the two groups were compared the total effective rate after treatment, the clearance rate of Helicobacter pylori and the incidence of adverse reactions. Results: The total effective rate of the two groups of patients after treatment, the clearance rate of Helicobacter pylori by comparing the difference was not statistically significant (P> 0.05); the incidence of adverse reactions in the observation group was 7.14% lower than the control group 26.19% (P <0.05). Conclusion: The clinical efficacy of Lactobacillus bifidum triple viable bacterium tablets in combination with standard “quadruple” therapy is similar to the standard “quadruple” therapy in patients with H. pylori infection, but the adverse reactions occurred during the treatment Lower rate.